多索茶碱联合甲强龙治疗急性加重期COPD患者的疗效及对血清炎症因子水平的影响

doi:10.3969/j.issn.1001-8131.2023.02.002

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (458 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the value of chronic obstructive pulmonary disease patients with acute exacerbation and the serum inflammatory factor level and clinical efficacy as the goal of the combined treatment of doxophylline and mJ. Methods 74 Patients were divided into two groups according to the random table method 1：1.The control group（n=37）was treated with polytheophylline,and the observation group（n=37）was treated with polytheophylline,with therapeutic efficacy,serum inflammatory factor and lung function,and the effects of different drug treatment were analyzed. Results After treatment as the judgment time,the clinical efficacy analysis,the control group was lower than the observation group,i.e.83.78% <97.30%（P<0.05）.Before treatment as the determination time,the difference between pulmonary function index and inflammatory factor level was small（P>0.05）;after treatment as the determination time,and the observation group was better than the control group（P<0.05）. Conclusion The clinical treatment effect of doxophylline combined with methylJohnson in patients with acute exacerbations is relatively significant,which is conducive to the decline of the level of inflammatory factors,the improvement of pulmonary respiratory function,and the high clinical application value.

Key words： Acute exacerbation of COPD mectyrosome doxophylline serum inflammatory factors

Received: 05 December 2022

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhao Li

Cite this article:

Zhao Li. Efficacy of Doxthelline Combined with Methyl Johnson in COPD Patients with Acute Exacerbation and Its Effect on Serum Inflammatory Factor Levels[J]. journal1, 2023, 43(2): 5-7.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2023.02.002 OR http://www.hrbyybjb.org.cn/EN/Y2023/V43/I2/5

[1] 夏晓玲,张艳.多索茶碱联合桉柠蒎治疗慢性阻塞性肺疾病急性发作期的疗效及对TLR4-MyD88通路的调控[J].西北药学杂志,2020,35(06):911-914.
[2] 朱卫波. 甲强龙联合多索茶碱对慢性阻塞性肺病患者血清脂联素、MMP-9、IL-17、IL-10及TNF-α水平的影响[J].海南医学院学报,2016,22(12):1214-1216,1220.
[3] 姜涛,詹茂芹,韦伟.布地奈德联合多索茶碱对慢性阻塞性肺疾病急性期降钙素原及脑钠肽的影响[J].新疆医科大学学报,2021,44(05):591-594.
[4] 易方莲,易松涛.慢性阻塞性肺疾病流行病学调查和防控措施研究[J].解放军预防医学杂志,2018,36(2):171-173,180.
[5] 潘子涵,迟春花,郑家强.基层医疗机构慢性阻塞性肺疾病筛查方法研究现状[J].中国全科医学,2020,23(3):257-266
[6] 王利忠. 慢阻肺患者急性加重期应用茶碱类药物治疗的效果和安全性分析[J].世界最新医学信息文摘(连续型电子期刊),2021,21(24):183-184.
[7] 高振云. 噻托溴铵粉联合多索茶碱对慢性阻塞性肺疾病患者肺功能与心理状态的影响[J].现代医学与健康研究电子杂志,2021,5(07):66-68.
[8] 金妍,石志华,周晓静.布地奈德混悬液联合多索茶碱对慢性阻塞性肺疾病患者疗效、肺功能及血气分析的影响[J].解放军医药杂志,2021,33(03):63-67.
[9] 陈洁,徐碧云,黄雅菲.多索茶碱对脂多糖诱导肺泡上皮细胞炎性损伤及NLRP3/IL-1β通路的影响[J].热带医学杂志,2021,21(03):296-300+329+394.
[10] 张鸿,邱玉明,林倍州,罗枫敏,徐效峰.三联雾化吸入治疗COPD急性加重期患者的疗效及对肺功能、血清炎症因子的影响[J].中南医学科学杂志,2022,50(03):442-445.
[11] 董继国. 多索茶碱与噻托溴铵联合治疗慢性阻塞性肺疾病的疗效研究[J].世界临床医学,2016,10(16):97.
[12] 邹晓平. 多索茶碱与噻托溴铵粉联合应用治疗慢阻肺患者对其肺功能的影响[J].当代医学,2021,27(9):133-135.
[13] 江伟青,肖根香.乙酰半胱氨酸联合多索茶碱对慢性阻塞性肺疾病急性加重期患者运动耐力及肺功能的影响[J].药品评价,2020,17(24):59-61.
[14] 吴军,阳辉,谢永根.多索茶碱对慢性阻塞性肺疾病急性发作患者气道重塑及呼吸功能的影响[J].临床合理用药杂志,2020,13(35):110-111+178.
[15] 包金兰,黄灿霞,蒋捷羽,安妮,孙润陆,张玉玲.非糖尿病急性冠脉综合征住院患者HDL-C、LDL-C/HDL-C水平回顾性分析[J].中山大学学报(医学科学版),2015,36(6):906-911.
[16] 朱卫波. 甲强龙联合多索茶碱对慢性阻塞性肺病患者血清脂联素、MMP-9、IL-17、IL-10及TNF-α水平的影响[J].海南医学院学报,2016,22(12):1214-1216,1220.
[17] 卢鹏,马桂.丹车附子汤结合耳穴压丸对肺心病急性加重期患者疗效、心肺功能及血清炎症因子水平影响研究[J].四川中医,2021,39(06):68-71.